Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 8;39(11):1450-1452.
doi: 10.1016/j.ccell.2021.09.004. Epub 2021 Nov 8.

A rare insight into the immunosuppressive landscape of prostate cancer bone metastases

Claudia Palena  1 , James L Gulley  2
Affiliations
Comment

A rare insight into the immunosuppressive landscape of prostate cancer bone metastases

Claudia Palena et al. Cancer Cell. .

Abstract

Therapeutic options for metastatic prostate cancer patients are currently limited. In this issue of Cancer Cell, Kfoury et al. characterized the tumor and immune compartments of prostate cancer bone metastasis, revealing a mechanism of immunosuppression that involves infiltration with M2 macrophages and T cell exhaustion mediated by the CCL20-CCR6 axis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The National Cancer Institute has Cooperative Research and Development Agreements (CRADAs) with EMD Serono, ImmunityBio, and Bavarian Nordic. These CRADAs provide resources for co-development of experimental agents. C.P. discloses spouse’s employment with and holdings in MacroGenics, Inc.

Figures

Figure 1.
Figure 1.. The immunosuppressive landscape of prostate cancer bone metastases
Major immunosuppressive cell populations in the microenvironment of bone metastases of prostate cancer include tumor-associated macrophages (TAM) of the immunosuppressive M2 type as well as tumor inflammatory monocyte (TIM) populations. In addition to being enriched with myeloid cells, bone metastases of prostate cancer show increased numbers of CD4+ TH1/TH17 cells and cytotoxic CD8+ T cells (CTLs); and the latter are characterized by markers of T cell exhaustion and low (dysfunctional) cytotoxic activity. Upregulation of the CCL20/CCR6 axis has been proposed as a driver of CD8+ T cell exhaustion in the context of prostate cancer that is metastatic to bone, resulting in prostate cancer immune evasion.
See this image and copyright information in PMC

Comment on

  • Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
    Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, Brouse T, Scadden EW, Igolkina AA, Kokkaliaris K, Choi BD, Barkas N, Randolph MA, Shin JH, Saylor PJ, Scadden DT, Sykes DB, Kharchenko PV; as part of the Boston Bone Metastases Consortium. Kfoury Y, et al. Cancer Cell. 2021 Nov 8;39(11):1464-1478.e8. doi: 10.1016/j.ccell.2021.09.005. Epub 2021 Oct 15. Cancer Cell. 2021. PMID: 34719426 Free PMC article.

References

    1. DeNardo DG, and Ruffell B (2019). Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369–382. 10.1038/s41577-019-0127-6. - DOI - PMC - PubMed
    1. Guerriero JL (2018). Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol. Med. 24, 472–489. 10.1016/j.molmed.2018.03.006. - DOI - PMC - PubMed
    1. Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, Zhao J, Anderson RN, Henley SJ, Yabroff KR, et al. (2021). Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J. Natl. Cancer Inst, djab131. 10.1093/jnci/djab131. - DOI - PMC - PubMed
    1. Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, Brouse T, Scadden EW, Igolkina AA, Kokkaliaris K, et al. (2021). Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 39, 1464–1478.e9. - PMC - PubMed
    1. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, and Schlom J (2020). Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J. Immunother. Cancer 8, e000433. 10.1136/jitc-2019-000433. - DOI - PMC - PubMed

Publication types